Steatotic liver disease in patients with chronic hepatitis C

Table 1 Baseline characteristics in the steatotic liver disease and non-steatotic liver disease groups, n (%)

Parameter	SLD (n = 290)	Non-SLD (n = 398)	P value
Age (years), median (Q1-Q3)	54 (38-64)	43.0 (35.0-62)	0.0007
Age ≥ 50	158 (54.5)	166 (41.7)	0.0009
Gender, women/men	109 (37.2)/182 (62.8)	235 (59.0)/163 (41.0)	< 0.0001
BMI (kg/m2), median (Q1-Q3)	26.5 (23.8-30)	24.6 (22.3-27)	< 0.0001
BMI ≥ 25 kg/m2	181 (62.4)	109 (27.4)	< 0.0001
Comorbidities
Any comorbidity	242 (83.4)	291 (73.1)	0.0014
Diabetes	41 (14.1)	32 (8.0)	0.0103
Obesity	75 (25.9)	42 (10.6)	< 0.0001
Autoimmune disorders	18 (6.2)	24 (6.0)	0.9238
Arterial hypertension	108 (37.2)	131 (32.9)	0.2392
Non-HCC tumors	17 (5.9)	30 (7.5)	0.3896
Renal disease	23 (7.9)	38 (9.5)	0.4613
Cholelithiasis	61 (21.0)	93 (23.4)	0.4686
Hyperlipidemia	50 (17.2)	39 (9.8)	0.0041
Concomitant medications	192 (66.2)	236 (59.3)	0.0649
HBV coinfection (HBsAg+)	1 (0.3)	2 (0.5)	0.7566
HIV coinfection	2 (0.7)	0	0.0971
IVDU current/past	5 (1.7)	9 (2.3)	0.7866
Alcohol abuse in the past	67 (23.1)	15 (3.8)	< 0.0001

SLD: Steatotic liver disease; Q: Quartile; BMI: Body mass index; HCC: Hepatocellular carcinoma; HBV: Hepatitis B virus; HBsAg: Hepatitis B surface antigen; HIV: Human immunodeficiency virus; IVDU: Intravenous drug use.